Abstract P1-11-10: Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

Authors: Niall Ashfield, Amira F. Mahdi, Neil T. Conlon, John Crown, Denis M. Collins

Published: 2023-03-02

DOI: 10.1158/1538-7445.sabcs22-p1-11-10

Source: Full article